Jingcheng Zhou (Kan Gong)

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 31

Top Topics

Advanced Non Small Cell Lung Cancer

Tyrosine Kinase

Positron Emission Tomography

Top Venues

Journal of medical genetics

Journal of cancer research and clinical oncology

Cell death & disease

Signal transduction and targeted therapy

This page only lists publications with an associated author ORCID identifier.

Publications

Jianhui Qiu, Ruiyi Deng, Zihou Zhao, Peidong Tian, Jingcheng Zhou
The long-term outcomes of local tumor destruction versus partial nephrectomy for cT1a non-clear cell renal cell carcinoma and development of prognostic nomograms. Journal of cancer research and clinical oncology 150 (3) (2024)
Jianhui Qiu, Ruiyi Deng, Zihou Zhao, Peidong Tian, Jingcheng Zhou
The long-term outcomes of local tumor destruction versus partial nephrectomy for cT1a non-clear cell renal cell carcinoma and development of prognostic nomograms. Journal of cancer research and clinical oncology 150 (3) (2024)
Jianhui Qiu, Ruiyi Deng, Zihou Zhao, Peidong Tian, Jingcheng Zhou
The long-term outcomes of local tumor destruction versus partial nephrectomy for cT1a non-clear cell renal cell carcinoma and development of prognostic nomograms. Journal of cancer research and clinical oncology 150 (3) (2024)
Jianhui Qiu, Ruiyi Deng, Zihou Zhao, Peidong Tian, Jingcheng Zhou
The long-term outcomes of local tumor destruction versus partial nephrectomy for cT1a non-clear cell renal cell carcinoma and development of prognostic nomograms. Journal of cancer research and clinical oncology 150 (3) (2024)
Jianhui Qiu, Ruiyi Deng, Zihou Zhao, Peidong Tian, Jingcheng Zhou
The long-term outcomes of local tumor destruction versus partial nephrectomy for cT1a non-clear cell renal cell carcinoma and development of prognostic nomograms. Journal of cancer research and clinical oncology 150 (3) (2024)
Jianhui Qiu, Ruiyi Deng, Zihou Zhao, Peidong Tian, Jingcheng Zhou
The long-term outcomes of local tumor destruction versus partial nephrectomy for cT1a non-clear cell renal cell carcinoma and development of prognostic nomograms. Journal of cancer research and clinical oncology 150 (3) (2024)
Xiaocong Pang, Xiaojiao Sun, Yanlun Gu, Xu He, Jingcheng Zhou, Song Song, Jixin Zhang, Jie Xia, Zhenming Liu, Yimin Cui
Discovery of C19-9 as a novel non-RGD inhibitor of αvβ3 to overcome enzalutamide resistance in castration-resistant prostate cancer. Signal transduction and targeted therapy 8 (1) (2023)
Xiaocong Pang, Xiaojiao Sun, Yanlun Gu, Xu He, Jingcheng Zhou, Song Song, Jixin Zhang, Jie Xia, Zhenming Liu, Yimin Cui
Discovery of C19-9 as a novel non-RGD inhibitor of αvβ3 to overcome enzalutamide resistance in castration-resistant prostate cancer. Signal transduction and targeted therapy 8 (1) (2023)
Xiaocong Pang, Xiaojiao Sun, Yanlun Gu, Xu He, Jingcheng Zhou, Song Song, Jixin Zhang, Jie Xia, Zhenming Liu, Yimin Cui
Discovery of C19-9 as a novel non-RGD inhibitor of αvβ3 to overcome enzalutamide resistance in castration-resistant prostate cancer. Signal transduction and targeted therapy 8 (1) (2023)
Xiaocong Pang, Xiaojiao Sun, Yanlun Gu, Xu He, Jingcheng Zhou, Song Song, Jixin Zhang, Jie Xia, Zhenming Liu, Yimin Cui
Discovery of C19-9 as a novel non-RGD inhibitor of αvβ3 to overcome enzalutamide resistance in castration-resistant prostate cancer. Signal transduction and targeted therapy 8 (1) (2023)
Wuping Yang, Zedan Zhang, Lei Li, Kenan Zhang, Yawei Xu, Mancheng Xia, Jingcheng Zhou, Yanqing Gong, Jinchao Chen, Jingcheng Zhou
ZNF582 overexpression restrains the progression of clear cell renal cell carcinoma by enhancing the binding of TJP2 and ERK2 and inhibiting ERK2 phosphorylation. Cell death & disease 14 (3) (2023)
Wuping Yang, Zedan Zhang, Lei Li, Kenan Zhang, Yawei Xu, Mancheng Xia, Jingcheng Zhou, Yanqing Gong, Jinchao Chen, Jingcheng Zhou
ZNF582 overexpression restrains the progression of clear cell renal cell carcinoma by enhancing the binding of TJP2 and ERK2 and inhibiting ERK2 phosphorylation. Cell death & disease 14 (3) (2023)
Wuping Yang, Zedan Zhang, Lei Li, Kenan Zhang, Yawei Xu, Mancheng Xia, Jingcheng Zhou, Yanqing Gong, Jinchao Chen, Jingcheng Zhou
ZNF582 overexpression restrains the progression of clear cell renal cell carcinoma by enhancing the binding of TJP2 and ERK2 and inhibiting ERK2 phosphorylation. Cell death & disease 14 (3) (2023)
Xiaocong Pang, Xiaojiao Sun, Yanlun Gu, Xu He, Jingcheng Zhou, Song Song, Jixin Zhang, Jie Xia, Zhenming Liu, Yimin Cui
Discovery of C19-9 as a novel non-RGD inhibitor of αvβ3 to overcome enzalutamide resistance in castration-resistant prostate cancer. Signal transduction and targeted therapy 8 (1) (2023)
Wuping Yang, Zedan Zhang, Lei Li, Kenan Zhang, Yawei Xu, Mancheng Xia, Jingcheng Zhou, Yanqing Gong, Jinchao Chen, Jingcheng Zhou
ZNF582 overexpression restrains the progression of clear cell renal cell carcinoma by enhancing the binding of TJP2 and ERK2 and inhibiting ERK2 phosphorylation. Cell death & disease 14 (3) (2023)
Kenan Zhang, Wuping Yang, Kaifang Ma, Jianhui Qiu, Lei Li, Yawei Xu, Zedan Zhang, Chaojian Yu, Jingcheng Zhou, Yanqing Gong, Lin Cai, Jingcheng Zhou
Genotype-phenotype correlations and clinical outcomes of patients with von Hippel-Lindau disease with large deletions. Journal of medical genetics 60 (5) (2022)
Kenan Zhang, Wuping Yang, Kaifang Ma, Jianhui Qiu, Lei Li, Yawei Xu, Zedan Zhang, Chaojian Yu, Jingcheng Zhou, Yanqing Gong, Lin Cai, Jingcheng Zhou
Genotype-phenotype correlations and clinical outcomes of patients with von Hippel-Lindau disease with large deletions. Journal of medical genetics 60 (5) (2022)
Zedan Zhang, Yanlin Tang, Lei Li, Wuping Yang, Yawei Xu, Jingcheng Zhou, Kaifang Ma, Kenan Zhang, Hongkai Zhuang, Yanqing Gong, Jingcheng Zhou
Downregulation of FXYD2 Is Associated with Poor Prognosis and Increased Regulatory T Cell Infiltration in Clear Cell Renal Cell Carcinoma. Journal of immunology research 2022 (2022)
Kenan Zhang, Wuping Yang, Kaifang Ma, Jianhui Qiu, Lei Li, Yawei Xu, Zedan Zhang, Chaojian Yu, Jingcheng Zhou, Yanqing Gong, Lin Cai, Jingcheng Zhou
Genotype-phenotype correlations and clinical outcomes of patients with von Hippel-Lindau disease with large deletions. Journal of medical genetics 60 (5) (2022)
Kenan Zhang, Wuping Yang, Kaifang Ma, Jianhui Qiu, Lei Li, Yawei Xu, Zedan Zhang, Chaojian Yu, Jingcheng Zhou, Yanqing Gong, Lin Cai, Jingcheng Zhou
Genotype-phenotype correlations and clinical outcomes of patients with von Hippel-Lindau disease with large deletions. Journal of medical genetics 60 (5) (2022)
Kenan Zhang, Wuping Yang, Kaifang Ma, Jianhui Qiu, Lei Li, Yawei Xu, Zedan Zhang, Chaojian Yu, Jingcheng Zhou, Yanqing Gong, Lin Cai, Jingcheng Zhou
Genotype-phenotype correlations and clinical outcomes of patients with von Hippel-Lindau disease with large deletions. Journal of medical genetics 60 (5) (2022)
Kenan Zhang, Wuping Yang, Zedan Zhang, Kaifang Ma, Lei Li, Yawei Xu, Jianhui Qiu, Chaojian Yu, Jingcheng Zhou, Lin Cai, Yanqing Gong, Jingcheng Zhou
A Novel Cuproptosis-Related Prognostic Model and the Hub Gene FDX1 Predict the Prognosis and Correlate with Immune Infiltration in Clear Cell Renal Cell Carcinoma. Journal of oncology 2022 (2022)
Jingcheng Zhou, Jingcheng Zhou
Belzutifan: a novel therapy for von Hippel-Lindau disease. Nature reviews. Nephrology 18 (4) (2022)
Kenan Zhang, Wuping Yang, Zedan Zhang, Kaifang Ma, Lei Li, Yawei Xu, Jianhui Qiu, Chaojian Yu, Jingcheng Zhou, Lin Cai, Yanqing Gong, Jingcheng Zhou
A Novel Cuproptosis-Related Prognostic Model and the Hub Gene FDX1 Predict the Prognosis and Correlate with Immune Infiltration in Clear Cell Renal Cell Carcinoma. Journal of oncology 2022 (2022)
Haibiao Xie, Kaifang Ma, Kenan Zhang, Jingcheng Zhou, Lei Li, Wuping Yang, Yanqing Gong, Lin Cai, Jingcheng Zhou
Cell-cycle arrest and senescence in TP53-wild type renal carcinoma by enhancer RNA-P53-bound enhancer regions 2 (p53BER2) in a p53-dependent pathway. Cell death & disease 12 (1) (2021)
Kenan Zhang, Jianhui Qiu, Wuping Yang, Kaifang Ma, Lei Li, Haibiao Xie, Yawei Xu, Yanqing Gong, Jingcheng Zhou, Lin Cai, Jingcheng Zhou
Clinical characteristics and risk factors for survival in affected offspring of von Hippel-Lindau disease patients. Journal of medical genetics 59 (10) (2021)
Yawei Xu, Lei Li, Wuping Yang, Kenan Zhang, Kaifang Ma, Haibiao Xie, Jingcheng Zhou, Lin Cai, Yanqing Gong, Zheng Zhang, Jingcheng Zhou
Association between vasectomy and risk of prostate cancer: a meta-analysis. Prostate cancer and prostatic diseases 24 (4) (2021)
Wuping Yang, Lei Li, Kenan Zhang, Kaifang Ma, Yanqing Gong, Jingcheng Zhou, Jingcheng Zhou
CLDN10 associated with immune infiltration is a novel prognostic biomarker for clear cell renal cell carcinoma. Epigenomics 13 (1) (2020)
Haibiao Xie, Kaifang Ma, Jiufeng Zhang, Baoan Hong, Jingcheng Zhou, Lei Li, Kenan Zhang, Jingcheng Zhou, Lin Cai
Novel genetic characterisation and phenotype correlation in von Hippel-Lindau (VHL) disease based on the Elongin C binding site: a large retrospective study. Journal of medical genetics 57 (11) (2020)
Xiang Peng, Jinchao Chen, Jiangyi Wang, Shuanghe Peng, Shengjie Liu, Kaifang Ma, Jingcheng Zhou, Baoan Hong, Bowen Zhou, Jiufeng Zhang, Lin Cai, Jingcheng Zhou
Natural history of renal tumours in von Hippel-Lindau disease: a large retrospective study of Chinese patients. Journal of medical genetics 56 (6) (2019)
Jiang-Yi Wang, Shuang-He Peng, Xiang-Hui Ning, Teng Li, Sheng-Jie Liu, Jia-Yuan Liu, Bao-An Hong, Nie-Nie Qi, Xiang Peng, Bo-Wen Zhou, Jiu-Feng Zhang, Lin Cai, Jingcheng Zhou
Shorter telomere length increases age-related tumor risks in von Hippel-Lindau disease patients. Cancer medicine 6 (9) (2017)